Han Ki Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Han Ki Park has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Young Hwan Park
Division of Cardiovascular Surgery, Department of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
36 shared publications - Jae Young Choi
Division of Pediatric Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
14 shared publications Yu Rim Shin
Division of Cardiovascular Surgery, Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Severance Cardiovascular Hospital, Seoul, Republic of Korea
13 shared publications- Hong Ju Shin
Department of Thoracic and Cardiovascular Surgery, Myoungju Hospital, Yongin, Republic of Korea
10 shared publications Hong Ju Shin
Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea
8 shared publicationsJo Won Jung
Division of Pediatric Cardiology, Congenital Heart Disease Center, Severance Cardiovascular Hospital, Yonsei University College of Medicine
8 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (6) , 484-485
Beyond morphometry: the atrial septal defect pressure gradient as a dynamic predictor of mitral valve growth in borderline left hearts
- 15 June 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (6) , 484-485
Open AccessBeyond morphometry: the atrial septal defect pressure gradient as a dynamic predictor of mitral valve growth in borderline left hearts
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (7) , 630-632
The Quest for Longevity in Pulmonary Valve Replacement: Translating Experimental Insights Into Surgical Excellence
Park HK. Korean Circ J. 2026 ;56:e105. https://doi.org/10.4070/kcj.2026.0061
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (7) , 630-632
Open AccessThe Quest for Longevity in Pulmonary Valve Replacement: Translating Experimental Insights Into Surgical Excellence
Park HK. Korean Circ J. 2026 ;56:e105. https://doi.org/10.4070/kcj.2026.0061
- Open Access
- 1 January 2025
- Published by XMLink in Yonsei Medical Journal
- Vol. 66 (6) , 390-394
Patient with Behçet Syndrome with Subaortic Pseudoaneurysm Who Underwent the Bentall Operation Showed Improvement after Medical Treatment
Lee H, et al. Yonsei Med J. 2025 Mar;66:e38. https://doi.org/10.3349/ymj.2023.0186
- 1 January 2025
- Published by XMLink in Yonsei Medical Journal
- Vol. 66 (6) , 390-394
Open AccessPatient with Behçet Syndrome with Subaortic Pseudoaneurysm Who Underwent the Bentall Operation Showed Improvement after Medical Treatment
Lee H, et al. Yonsei Med J. 2025 Mar;66:e38. https://doi.org/10.3349/ymj.2023.0186
- Open Access
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (10) , 669-671
Long-term Outcomes of Fontan Operation in Korea: Different Regions, Different Patients, Different Prognostic Factors?
Park HK. Korean Circ J. 2024 Oct;54(10):669-671. https://doi.org/10.4070/kcj.2024.0291
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (10) , 669-671
Open AccessLong-term Outcomes of Fontan Operation in Korea: Different Regions, Different Patients, Different Prognostic Factors?
Park HK. Korean Circ J. 2024 Oct;54(10):669-671. https://doi.org/10.4070/kcj.2024.0291
- Open Access
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (2) , 91-92
Cone Reconstruction for Ebstein’s Anomaly: Is It Durable in Pediatric Patients?
Park HK. Korean Circ J. 2024 Jan;54:e20. https://doi.org/10.4070/kcj.2024.0007
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (2) , 91-92
Open AccessCone Reconstruction for Ebstein’s Anomaly: Is It Durable in Pediatric Patients?
Park HK. Korean Circ J. 2024 Jan;54:e20. https://doi.org/10.4070/kcj.2024.0007
- Open Access
- 23 November 2023
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 57 (1) , 1-24
2023 KASNet Guidelines on Atrial Fibrillation Surgery
Hyung Gon Je, Jae Woong Choi, Ho Young Hwang, Ho Jin Kim, Joon Bum Kim, Hee-Jung Kim, Jae-Sung Choi, Dong Seop Jeong, Jae Gun Kwak, Han Ki Park, Seung Hyun Lee, Cheong Lim, Jae Won Lee, for the KASNet Guideline Writing Committee. J Chest Surg 2024;57:1-24. https://doi.org/10.5090/jcs.23.127
- 23 November 2023
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 57 (1) , 1-24
Open Access2023 KASNet Guidelines on Atrial Fibrillation Surgery
Hyung Gon Je, Jae Woong Choi, Ho Young Hwang, Ho Jin Kim, Joon Bum Kim, Hee-Jung Kim, Jae-Sung Choi, Dong Seop Jeong, Jae Gun Kwak, Han Ki Park, Seung Hyun Lee, Cheong Lim, Jae Won Lee, for the KASNet Guideline Writing Committee. J Chest Surg 2024;57:1-24. https://doi.org/10.5090/jcs.23.127
- Open Access
- 17 November 2022
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 63 (12) , 1144-1146
Heart Transplantation in a Patient with Complex Congenital Heart Disease, Physiologic Single Lung, and Severe Pulmonary Hypertension
Lee HW, et al. Yonsei Med J. 2022 Dec;63(12):1144-1146. https://doi.org/10.3349/ymj.2022.0384
- 17 November 2022
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 63 (12) , 1144-1146
Open AccessHeart Transplantation in a Patient with Complex Congenital Heart Disease, Physiologic Single Lung, and Severe Pulmonary Hypertension
Lee HW, et al. Yonsei Med J. 2022 Dec;63(12):1144-1146. https://doi.org/10.3349/ymj.2022.0384
- 1 October 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 164 (4) , 1176-1185.e3
Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation
- 1 October 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 164 (4) , 1176-1185.e3
Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation
- Open Access
Is It Possible for Children in Duchenne Muscular Dystrophy to Preserve Cardiac Function with Medical Assistance?
In patients with Duchenne muscular dystrophy (DMD), death secondary to cardiac or respiratory failure typically occurs in the second or third decade without treatment. Although cardiac dysfunction is treated with standard heart-failure strategies, it remains insufficient in DMD children. The purpose of this study was to evaluate the efficiency of cardiac medication and noninvasive ventilator support in DMD cardiomyopathy children with analyzing echocardiographic data. Forty-eight DMD children patients were included and divided into 2 groups by left ventricular (LV) ejection fraction (EF) at the time of initial treatment. Group 1: LV EF ≥ 45% and Group 2: LV EF < 45%. p-values were calculated using a Linear mixed model to estimate the association between cardiac medications and echocardiographic measurements. Before and after cardiac medications, the change values were significantly different in interventricular septal thickness at end diastole (IVSd), interventricular septal thickness at end systole (IVSs), left ventricular internal diameter end systole (LVIDs), left ventricular posterior wall thickness end diastole (LVPWd), ejection fraction (EF), fractional shortening (FS), deceleration time (DT), DT slope, Lat A’ and Lat E/E’ (p < 0.05). Group 2 patients revealed to take more kinds of cardiac medications than Group 1 (p < 0.05) including ACEIs, beta-blocker, and inotropics, then LV EF was better preserved in Group 2 than Group 1. It is certainly helpful to take individualized medical combination therapy including inotropic agents for cardiomyopathy in DMD children patients with EF < 45%.
Open AccessIs It Possible for Children in Duchenne Muscular Dystrophy to Preserve Cardiac Function with Medical Assistance?
In patients with Duchenne muscular dystrophy (DMD), death secondary to cardiac or respiratory failure typically occurs in the second or third decade without treatment. Although cardiac dysfunction is treated with standard heart-failure strategies, it remains insufficient in DMD children. The purpose of this study was to evaluate the efficiency of cardiac medication and noninvasive ventilator support in DMD cardiomyopathy children with analyzing echocardiographic data. Forty-eight DMD children patients were included and divided into 2 groups by left ventricular (LV) ejection fraction (EF) at the time of initial treatment. Group 1: LV EF ≥ 45% and Group 2: LV EF < 45%. p-values were calculated using a Linear mixed model to estimate the association between cardiac medications and echocardiographic measurements. Before and after cardiac medications, the change values were significantly different in interventricular septal thickness at end diastole (IVSd), interventricular septal thickness at end systole (IVSs), left ventricular internal diameter end systole (LVIDs), left ventricular posterior wall thickness end diastole (LVPWd), ejection fraction (EF), fractional shortening (FS), deceleration time (DT), DT slope, Lat A’ and Lat E/E’ (p < 0.05). Group 2 patients revealed to take more kinds of cardiac medications than Group 1 (p < 0.05) including ACEIs, beta-blocker, and inotropics, then LV EF was better preserved in Group 2 than Group 1. It is certainly helpful to take individualized medical combination therapy including inotropic agents for cardiomyopathy in DMD children patients with EF < 45%.
- Open Access
Novel Therapeutic Effects of Pterosin B on Ang II-Induced Cardiomyocyte Hypertrophy
Pathological cardiac hypertrophy is characterized by an abnormal increase in cardiac muscle mass in the left ventricle, resulting in cardiac dysfunction. Although various therapeutic approaches are being continuously developed for heart failure, several studies have suggested natural compounds as novel potential strategies. Considering relevant compounds, we investigated a new role for Pterosin B for which the potential life-affecting biological and therapeutic effects on cardiomyocyte hypertrophy are not fully known. Thus, we investigated whether Pterosin B can regulate cardiomyocyte hypertrophy induced by angiotensin II (Ang II) using H9c2 cells. The antihypertrophic effect of Pterosin B was evaluated, and the results showed that it reduced hypertrophy-related gene expression, cell size, and protein synthesis. In addition, upon Ang II stimulation, Pterosin B attenuated the activation and expression of major receptors, Ang II type 1 receptor and a receptor for advanced glycation end products, by inhibiting the phosphorylation of PKC-ERK-NF-κB pathway signaling molecules. In addition, Pterosin B showed the ability to reduce excessive intracellular reactive oxygen species, critical mediators for cardiac hypertrophy upon Ang II exposure, by regulating the expression levels of NAD(P)H oxidase 2/4. Our results demonstrate the protective role of Pterosin B in cardiomyocyte hypertrophy, suggesting it is a potential therapeutic candidate.
Open AccessNovel Therapeutic Effects of Pterosin B on Ang II-Induced Cardiomyocyte Hypertrophy
Pathological cardiac hypertrophy is characterized by an abnormal increase in cardiac muscle mass in the left ventricle, resulting in cardiac dysfunction. Although various therapeutic approaches are being continuously developed for heart failure, several studies have suggested natural compounds as novel potential strategies. Considering relevant compounds, we investigated a new role for Pterosin B for which the potential life-affecting biological and therapeutic effects on cardiomyocyte hypertrophy are not fully known. Thus, we investigated whether Pterosin B can regulate cardiomyocyte hypertrophy induced by angiotensin II (Ang II) using H9c2 cells. The antihypertrophic effect of Pterosin B was evaluated, and the results showed that it reduced hypertrophy-related gene expression, cell size, and protein synthesis. In addition, upon Ang II stimulation, Pterosin B attenuated the activation and expression of major receptors, Ang II type 1 receptor and a receptor for advanced glycation end products, by inhibiting the phosphorylation of PKC-ERK-NF-κB pathway signaling molecules. In addition, Pterosin B showed the ability to reduce excessive intracellular reactive oxygen species, critical mediators for cardiac hypertrophy upon Ang II exposure, by regulating the expression levels of NAD(P)H oxidase 2/4. Our results demonstrate the protective role of Pterosin B in cardiomyocyte hypertrophy, suggesting it is a potential therapeutic candidate.